Top

Published in:

Open Access 01-04-2021 | Anticoagulant

Anticoagulant treatment in COVID-19: a narrative review

Authors: Vincenzo Carfora, Giorgio Spiniello, Riccardo Ricciolino, Marco Di Mauro, Marco Giuseppe Migliaccio, Filiberto Fausto Mottola, Nicoletta Verde, Nicola Coppola, Vanvitelli COVID-19 group

Published in: Journal of Thrombosis and Thrombolysis | Issue 3/2021

Abstract

The actual Coronavirus Disease (COVID 19) pandemic is due to Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a member of the coronavirus family. Besides the respiratory involvement, COVID 19 patients frequently develop a pro-coagulative state caused by virus-induced endothelial dysfunction, cytokine storm and complement cascade hyperactivation. It is common to observe diffuse microvascular thrombi in multiple organs, mostly in pulmonary microvessels. Thrombotic risk seems to be directly related to disease severity and worsens patients’ prognosis. Therefore, the correct understanding of the mechanisms underlying COVID-19 induced prothrombotic state can lead to a thorough assessment of the possible management strategies. Hence, we review the pathogenesis and therapy of COVID 19-related thrombosis disease, focusing on the available evidence on the possible treatment strategies and proposing an algorithm for the anticoagulation strategy based on disease severity.

Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB (2020) Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA. https://doi.org/10.1001/jama.2020.6019CrossRefPubMedPubMedCentral

Hoffmann M, Kleine-Weber H, Schroeder S et al (2020) SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181(2):271–280.e8. https://doi.org/10.1016/j.cell.2020.02.052CrossRefPubMedPubMedCentral

Zhou F, Yu T, Du R et al (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395:1054–1062CrossRefPubMedPubMedCentral

Li R, Pei S, Chen B et al (2020) Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2). Science 368(6490):489–493. https://doi.org/10.1126/science.abb3221CrossRefPubMedPubMedCentral

Sardu C, D'Onofrio N, Balestrieri ML et al (2020) Outcomes in patients with hyperglycemia affected by COVID-19: can we do more on glycemic control? Diabetes Care 43(7):1408–1415. https://doi.org/10.2337/dc20-0723CrossRefPubMedPubMedCentral

Poissy J, Goutay J, Caplan M, Parmentier E, Duburcq T, Lassalle F, Jeanpierre E, Rauch A, Labreuche J, Susen S, Lille ICU Haemostasis COVID-19 group (2020) Pulmonary embolism in COVID-19 patients: awareness of an increased prevalence. Circulation. https://doi.org/10.1161/CIRCULATIONAHA.120.047430CrossRefPubMedPubMedCentral

Carsana L, Sonzogni A, Nasr A et al (2020) Pulmonary post-mortem findings in a large series of COVID-19 cases from Northern Italy. medRxiv. https://doi.org/10.1101/2020.04.19.20054262CrossRef

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J et al (2020) Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. https://doi.org/10.1001/jama.2020.1585CrossRefPubMedPubMedCentral

Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y et al (2020) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395(10223):507–513. https://doi.org/10.1016/S0140-6736(20)30211-7CrossRefPubMedPubMedCentral

10.

Lippi G, Favaloro EJ (2020) D-dimer is associated with severity of coronavirus disease 2019 (COVID-19): a pooled analysis. Thromb Haemost. https://doi.org/10.1055/s-0040-1709650CrossRefPubMedPubMedCentral

11.

Tang N, Li D, Wang X, Sun Z (2020) Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. https://doi.org/10.1111/jth.14768CrossRefPubMedPubMedCentral

12.

Luo W, Yu H, Gou J et al (2020) Clinical pathology of critical patient with novel coronavirus pneumonia (COVID-19). Preprints 2020020407

13.

Konstantinides SV, Meyer G, Becattini C et al (2020) 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 41:543–603CrossRefPubMed

14.

Libby P, Simon DI (2001) Inflammation and thrombosis: the clot thickens. Circulation 103:1718–1720CrossRefPubMed

15.

Qin C, Zhou L, Hu Z et al (2020) Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis 71:762–768CrossRefPubMed

16.

Branchford BR, Carpenter SL (2018) The role of inflammation in venous thromboembolism. Front Pediatr 6:142CrossRefPubMedPubMedCentral

17.

José RJ, Williams AE, Chambers RC (2014) Proteinase activated receptors in fibroproliferative lung disease. Thorax 69:190–192CrossRefPubMed

18.

Chambers RC, Scotton CJ (2012) Coagulation cascade proteinases in lung injury and fibrosis. Proc Am Thorac Soc 9:96–101CrossRefPubMed

19.

Campbell CM, Kahwash R (2020) Will complement inhibition be the new target in treating COVID-19 related systemic thrombosis? Circulation. https://doi.org/10.1161/CIRCULATIONAHA.120.047419CrossRefPubMedPubMedCentral

20.

Merle NS, Noe R, Halbwachs-Mecarelli L, Fremeaux-Bacchi V, Roumenina LT (2015) Complement system part II: role in immunity. Front Immunol 6:257. https://doi.org/10.3389/fimmu.2015.00257CrossRefPubMedPubMedCentral

21.

Ikeda K, Nagasawa K, Horiuchi T, Tsuru T, Nishizaka H, Niho Y (1997) C5a induces tissue factor activity on endothelial cells. Thromb Haemost 77(2):394–398CrossRefPubMed

22.

Sauter RJ, Sauter M, Reis ES et al (2019) Functional relevance of the anaphylatoxin receptor C3aR for platelet function and arterial thrombus formation marks an intersection point between innate immunity and thrombosis [published correction appears]. Circulation 139(3):e8

23.

Umbrello M, Dyson A, Feelisch M et al (2013) The key role of nitric oxide in hypoxia: hypoxic vasodilation and energy supply-demand matching. Antioxid Redox Signal 19:1690–1710CrossRefPubMed

24.

Bonetti PO, Lerman LO, Lerman A (2003) Endothelial dysfunction—a marker of atherosclerotic risk. Arterioscl Throm Vas 23:168–175CrossRef

25.

Levi M, van der Poll T (2017) Coagulation and sepsis. Thromb Res 149:38–44CrossRefPubMed

26.

Semeraro N, Ammollo CT, Semeraro F, Colucci M (2015) Coagulopathy of acute sepsis. Semin Thromb Hemost 41:650–658CrossRefPubMed

27.

Schouten M, Wiersinga WJ, Levi M, van der Poll T (2008) Inflammation, endothelium, and coagulation in sepsis. J Leukoc Biol 83(3):536–545. https://doi.org/10.1189/jlb.0607373CrossRefPubMed

28.

Böger RH, Bode-Böger SM, Szuba A et al (1998) Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 98:1842–1847CrossRefPubMed

29.

Böger R, Hannemann J (2020) Dual role of the L-arginine-ADMA-NO pathway in systemic hypoxic vasodilation and pulmonary hypoxic vasoconstriction. Pulm Circ 10(2):2045894020918850. https://doi.org/10.1177/2045894020918850.eCollection2020Apr-JunCrossRefPubMed

30.

Dashti-Khavidaki S, Khalili H (2020) Considerations for statin therapy in patients with COVID-19. Pharmacotherapy 40(5):484–486. https://doi.org/10.1002/phar.2397CrossRefPubMedPubMedCentral

31.

Mehler PS, Coll JR, Estacio R, Esler A, Schrier RW, Hiatt WR (2003) Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes. Circulation 107(5):753–756CrossRefPubMed

32.

Böger RH, Sydow K, Borlak J et al (2000) LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases. Circ Res 87:99–105CrossRefPubMed

33.

Marinella MA (2020) Indomethacin and resveratrol as potential treatment adjuncts for SARS-CoV-2/COVID-19. Int J Clin Pract. https://doi.org/10.1111/ijcp.13535CrossRefPubMedPubMedCentral

34.

Varga Z, Flammer AJ, Steiger P et al (2020) Endothelial cell infection and endotheliitis in COVID-19. Lancet 395(10234):1417–1418. https://doi.org/10.1016/S0140-6736(20)30937-5CrossRefPubMedPubMedCentral

35.

Daiber A, Xia N, Steven S, Oelze M, Hanf A, Kröller-Schön S, Münzel T, Li H (2019) New therapeutic implications of endothelial nitric oxide synthase (eNOS) function/dysfunction in cardiovascular disease. Int J Mol Sci 20(1):E187. https://doi.org/10.3390/ijms20010187CrossRefPubMed

36.

Cattaneo M, Bertinato EM, Birocchi S, Brizio C, Malavolta D, Manzoni M, Muscarella G, Orlandi M (2020) Pulmonary embolism or pulmonary thrombosis in COVID-19? Is the recommendation to use high-dose heparin for thromboprophylaxis justified? Thromb Haemost. https://doi.org/10.1055/s-0040-1712097CrossRefPubMedPubMedCentral

37.

Xu X, Han M, Li T et al (2020) Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA 117(20):10970–10975. https://doi.org/10.1073/pnas.2005615117CrossRefPubMedPubMedCentral

38.

Diurno F, Numis FG, Porta G et al (2020) Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience. Eur Rev Med Pharmacol Sci 24(7):4040–4047. https://doi.org/10.26355/eurrev_202004_20875CrossRefPubMed

39.

Barbar S, Noventa F, Rossetto V et al (2010) A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost 8(11):2450–2457CrossRefPubMed

40.

Zhai Z, Li C, Chen Y et al (2020) Prevention and treatment of venous thromboembolism associated with coronavirus disease 2019 infection: a consensus statement before guidelines. Thromb Haemost. https://doi.org/10.1055/s-0040-1710019CrossRefPubMedPubMedCentral

41.

Tang N, Bai H, Chen X, Gong J, Li D, Sun Z (2020) Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. https://doi.org/10.1111/jth.14817CrossRefPubMedPubMedCentral

42.

Lin L, Lu L, Cao W, Li T (2020) Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect 9:727–732CrossRefPubMedPubMedCentral

43.

Gaertner F, Massberg S (2016) Blood coagulation in immunothrombosis—at the frontline of intravascular immunity. Semin Immunol 28:561–569CrossRefPubMed

44.

Thachil J (2020) The versatile heparin in COVID-19. J Thromb Haemost 18(5):1020–1022. https://doi.org/10.1111/jth.14821CrossRefPubMed

45.

Marfella R, Paolisso P, Sardu C et al (2020) Negative impact of hyperglycaemia on tocilizumab therapy in Covid-19 patients. Diabetes Metab S1262–3636(20):30082–30083. https://doi.org/10.1016/j.diabet.2020.05.005CrossRef

46.

Sagnelli C, Gentile V, Tirri R et al (2020) Chronic conventional disease-modifying anti-rheumatic drugs masking severe SARS-CoV-2 manifestations in an elderly rheumatic patient. J Infect S0163–4453(20):30322–30324. https://doi.org/10.1016/j.jinf.2020.05.043CrossRef

Title: Anticoagulant treatment in COVID-19: a narrative review
Authors: Vincenzo Carfora
Giorgio Spiniello
Riccardo Ricciolino
Marco Di Mauro
Marco Giuseppe Migliaccio
Filiberto Fausto Mottola
Nicoletta Verde
Nicola Coppola
Vanvitelli COVID-19 group
Publication date: 01-04-2021
Publisher: Springer US
Keywords: Anticoagulant
SARS-CoV-2
COVID-19
Thrombosis
Low Molecular Weight Heparin
Published in: Journal of Thrombosis and Thrombolysis / Issue 3/2021
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI: https://doi.org/10.1007/s11239-020-02242-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2021

Platelet count trends and response to fondaparinux in a cohort of heparin-induced thrombocytopenia suspected patients after pulmonary endarterectomy

Rescue catheter-based therapies for the treatment of acute massive pulmonary embolism after unsuccessful systemic thrombolysis

COVID-19 and its sequelae: a platform for optimal patient care, discovery and training

Can fibrinolytic therapy be clinically useful in severe pneumonia caused by COVID-19?

Stress hyperglycemia is predictive of worse outcome in patients with acute ischemic stroke undergoing intravenous thrombolysis

The clinical characteristic, diagnosis, treatment, and prognosis of cerebral cortical vein thrombosis: a systematic review of 325 cases

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage